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Abstract
Background. The dismal prognosis of glioblastoma (GBM) may be related to the ability of GBM cells to develop 
mechanisms of treatment resistance. We designed a protocol called Coordinated Undermining of Survival Paths 
combining 9 repurposed non-oncological drugs with metronomic temozolomide—version 3—(CUSP9v3) to ad-
dress this issue. The aim of this phase Ib/IIa trial was to assess the safety of CUSP9v3.
Methods. Ten adults with histologically confirmed GBM and recurrent or progressive disease were included. 
Treatment consisted of aprepitant, auranofin, celecoxib, captopril, disulfiram, itraconazole, minocycline, ritonavir, 
and sertraline added to metronomic low-dose temozolomide. Treatment was continued until toxicity or progres-
sion. Primary endpoint was dose-limiting toxicity defined as either any unmanageable grade 3–4 toxicity or ina-
bility to receive at least 7 of the 10 drugs at ≥ 50% of the per-protocol doses at the end of the second treatment 
cycle.
Results. One patient was not evaluable for the primary endpoint (safety). All 9 evaluable patients met the primary 
endpoint. Ritonavir, temozolomide, captopril, and itraconazole were the drugs most frequently requiring dose 
modification or pausing. The most common adverse events were nausea, headache, fatigue, diarrhea, and ataxia. 
Progression-free survival at 12 months was 50%.
Conclusions. CUSP9v3 can be safely administered in patients with recurrent GBM under careful monitoring. A ran-
domized phase II trial is in preparation to assess the efficacy of the CUSP9v3 regimen in GBM.
A phase Ib/IIa trial of 9 repurposed drugs combined 
with temozolomide for the treatment of recurrent 
glioblastoma: CUSP9v3
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Key Points
 • Glioblastoma escapes pharmacological treatment as a result of cellular 
heterogeneity and resistance mechanisms.
 • A treatment regimen with 9 different drugs (CUSP9v3) in addition to low-dose 
metronomic temozolomide was devised to tackle this issue.
 • CUSP9v3 is safe in patients with recurrent GBM.
As of fall 2020, current standard treatment of glioblastoma 
(GBM) with neurologically safe maximal resection, irradia-
tion and temozolomide leads to progression-free survival 
(PFS) of 6.7 months, overall survival (OS) of 16.0 months, 
and 2-year OS of 30.7%.1
Recurrence usually takes place within a year after ini-
tial treatment. There is no commonly accepted standard of 
care for recurrent GBM. No regimen has proven to be safe 
and markedly effective for this condition.2
In an attempt to address this unmet need, our group, 
together with many others, embarked on an exhaustive 
systematic search for already-marketed non-oncological 
drugs that might be able to set the stage for temozolomide 
to be more effective.3–9
A complex winnowing process led to the final selection 
of the 9 drugs of Coordinated Undermining of Survival 
Paths combining 9 repurposed non-oncological drugs 
with metronomic temozolomide—version 3 (CUSP9v3) on 
which we report here the first clinical experiences. Details 
of that selection process can be found in the background 
papers.4,7 Important criteria for drug selection were 1) ro-
bustness of preclinical data on GBM growth inhibition, 
2)  low side effect burden, 3)  clinical familiarity with the 
drug in its general medicine (non-oncology) role, 4) availa-
bility as a generic, non-proprietary drug, and finally 5) lack 
of predictable serious pharmacological interactions.4,7
The drugs of CUSP9v3 with their basic pharmacological at-
tributes are listed in Table 1. Briefly, aprepitant inhibits NK-1 
which is a growth-stimulating element in GBM.10 The anti-
rheumatoid arthritis drug auranofin inhibits thioredoxin re-
ductase, resulting in increased intracellular reactive oxygen 
species.11 The anti-hypertensive captopril reduces invasion, 
migration and adhesion of GBM cell activity through sol-
uble matrix metalloproteinase (MMP)-2 and MMP-9 inhibi-
tion.12 The analgesic celecoxib has long been shown to have 
anticancer properties related to cyclooxygenase-2 inhibition 
and has demonstrated encouraging results in combination 
with low-dose temozolomide.13,14 The alcohol deterrent disul-
firam is consistently cytotoxic to a wide range of cancer cells 
and is effective against GBM stem cells through aldehyde de-
hydrogenase inhibition.15 The antifungal itraconazole likely 
exerts its anticancer activity due to its multiple pharmaco-
logical effects16 with specific data in GBM pointing towards 
an effect on autophagy.17 The antibiotic minocycline has well-
characterized neuroprotective effects18 and reduces GBM 
growth and invasion.19 The anti-retroviral ritonavir is effective 
in mouse GBM models with temozolomide by inducing endo-
plasmic reticulum stress.20 Last, the antidepressant sertraline 
was included for its ability to inhibit P-glycoprotein at the 
blood-brain barrier21 and because of its safe use in GBM 
patients.22 Overall, these drugs were judged to have robust 
anti-glioma or temozolomide-augmenting effects as well as 
to meet the criteria 1 to 5 above.
CUSP9v3 also comprises low-dose, continuous 
temozolomide at 20  mg/m2 body surface area (BSA) p.o. 
twice daily, without interruption. This choice was based 
on past trials of various temozolomide schedules. After 
evaluating the 15 trials reviewed by Chen et al.23 and com-
paring these to data of Omuro et al., Clarke et al., and Reynés 
et  al.24–26 who used temozolomide at 50  mg/m2 BSA/day 
without interruption, that of Stockhammer et al.14 who used 
20 mg/m2 BSA/day and that of Zustovich et al.27 who used 
40 mg/m2 BSA/day, we concluded that any potential advan-
tage of higher dosing was small and offset by a strongly re-
duced side effect burden associated with a regimen of 50 mg/
m2 BSA/day or less. Kong et al. reported that temozolomide 
at the dose of 40 mg/m2 BSA/day was well-tolerated even in 
patients with Karnofsky Performance Status (KPS) < 70%.28 
We, therefore, chose 20 mg/m2 BSA given twice daily, the 
dose used by Zustovich et al. and Kong et al.27,28
Importance of the Study
In 2013, we proposed a new concept to treat pa-
tients with recurrent GBM called Coordinated 
Undermining of Survival Paths (CUSP). The 
CUSP concept attempts to block growth-driving 
signaling pathways active in GBM. We took 
advantage of repurposing already-marketed 
non-oncological drugs and looked at the ev-
idence for their ability to inhibit one or more 
of the identified GBM growth and cell sur-
vival pathways. Including pharmacology, drug 
interaction, and safety considerations, a list 
of 9 drugs was proposed to be used with low-
dose, continuous temozolomide (CUSP9v3). 
Here, we report the results from the first clinical 
trial of CUSP9v3. In 10 patients with recurrent 
glioblastoma, the regimen was well-tolerated. 
This work is the first step in establishing that an 
extensive multi-drug regimen is tolerable and 
should now be tested for its potential efficacy 
against GBM.











Although the safety profile of each drug of the CUSP9v3 
protocol is well-known, safety concerns may arise due to 
the risk of drug-drug interactions at the pharmacodynamic 
(eg, in form of additive toxicity) or pharmacokinetic level 
(with effects on metabolism or elimination, requiring dose 
adjustments or drug pausing). A database search prior to 
study initiation showed that clinically relevant interactions 
between CUSP9v3 drugs are expected to occur mainly 
due to CYP3A inhibition by itraconazole (strong), ritonavir 
(strong), and aprepitant (moderate). The unusual risks of 
using 10 daily drugs over a protracted period were partially 
offset by the good safety profile of each when used as a 
single drug and the intensity of our monitoring of patients.
We report here the results of the first trial of the CUSP9v3 
regimen for recurrent or progressive GBM.
Patients and Methods
Study Design
This is a phase Ib/IIa trial examining the safety of the 
CUSP9v3 regimen combined with temozolomide in pa-
tients with recurrent or progressive GBM. The primary 
endpoint was dose-limiting toxicity (DLT), and secondary 
endpoints were best tumor response, PFS, and OS. 
Dose-limiting toxicity was defined as either any unman-
ageable grade 3–4 toxicity at the end of the second treat-
ment cycle or inability to receive at least 7 of the 10 drugs, 
all of them being given at ≥ 50% of the target doses, at the 
end of the second treatment cycle. Best tumor response 
was defined as the best therapeutic effect recorded from 
the start of the treatment until the last follow-up according 
to Response Assessment in Neuro-Oncology (RANO) 
criteria.29
Overall survival was defined as the time in months be-
tween the CUSP9v3 induction cycle start date and the date 
of last follow-up or death of any cause, whichever came 
first. Patients alive at the time of the last follow-up were 
censored.
Progression-free survival was defined as the time be-
tween the CUSP9v3 induction cycle start date and the date 
of the last follow-up, progression according to RANO cri-
teria, or death of any cause, whichever came first. Patients 
with no progression and alive at the time of the last fol-
low-up were censored.
This study was approved by the institutional review 
board of Ulm University Hospital (approval number 112/16) 
and the German competent authority Bundesinstitut 
für Arzneimittel und Medizinprodukte (BfArM; refer-
ence number 4041326) and registered at clinicaltrials.gov 
(NCT02770378).
  













 10 h NK-1 receptors Constipation, dyspepsia, fatigue, ALAT increase, decreased appetite, head-
ache, hiccups
Auranofin None  10 d Thioredoxin, ROS 
generation, STAT3
Diarrhea, pruritus, exanthema
Captopril None    2 h ACE, AT1 recep-
tors, MMPs
Diarrhea, nausea, dry mouth, constipation, abdominal pain, vomiting, loss of 








Disulfiram 2E1 < 2 h ALDH, ROS gen-
eration
Nausea, vomiting, drowsiness/somnolence











Diarrhea, nausea, vomiting, dyspepsia, flatulence, dizziness, rash, urticaria, 
pruritus
Ritonavir 3A4    4 h P-gp efflux trans-
porters (weak), 
proteasome, Akt, 
mTOR, cyclin D3 
Pancreatitis, diarrhea, nausea, abdominal pain, vomiting, dyspepsia, fatigue, 
asthenia, flushing, feeling hot, increased amylase, decreased thyroxine, ar-
thralgia, back pain, dizziness, peripheral neuropathy, headache, paresthesia, 
dysgeusia, oropharyngeal pain, cough, pharyngitis, rash, pruritus
Sertraline Weak    1 d Akt, mTOR, TCTP Diarrhea, nausea, dry mouth, fatigue, dizziness, drowsiness/somnolence, 
headache, insomnia, ejaculation failure
ACE, angiotensin-converting enzyme; Akt, protein kinase B; ALAT, Alanine aminotransferase; ALDH, aldehyde dehydrogenase; AT1, angiotensin II 
receptor type 1; BCRP, breast cancer resistance protein; COX, cyclo-oxygenase; MMPs, matrix metalloproteinases; mTOR, mammalian target of 
rapamycin; NK-1, neurokinin-1; P-gp, P-glycoprotein; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription 3; TCTP, 
translationally controlled tumor protein.
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Sample Size
A sample size of 10 patients was selected to assess the pri-
mary endpoint. In this population, we expected a true rate 
of DLT of 40%. Sequential boundaries were used to mon-
itor the DLT rate with accrual to be halted if excessive num-
bers of DLTs were seen. A Pocock-type stopping boundary 
yielded a probability of crossing the boundaries of max-
imally 10% when the actual rate of DLT was equal to the 
expected rate of 40%.30 The boundaries are described in 
Supplementary Material 1.
Patients
Eligible patients were adults with histologically confirmed 
GBM and recurrent or progressive disease according to 
RANO criteria. In 3 cases, study inclusion was allowed 
based on early recurrence that had not yet met minimal 
RANO requirements (ie,  10 mm × 10 mm diameters) but 
was judged as recurrence by external radiologists and con-
firmed by the trial’s neuroradiologist (Be.S.). Patients with 
prior low-grade glioma were eligible if the malignant trans-
formation to GBM was histologically confirmed. Additional 
key eligibility criteria were: no more than 3 prior episodes 
of tumor progression, KPS of at least 70%, stable steroid 
dose for at least 1 week prior to the start of study treat-
ment, sufficient interval since last treatment (at least 4 
weeks for systemic treatment or surgery, at least 12 weeks 
for radiotherapy) and no known contraindication to any of 
the CUSP9v3 drugs.
Treatment Regimen
Treatment initiation encompassed the addition of the 
9 drugs to uninterrupted temozolomide as depicted in 
Supplementary Material 2 and comprised an induction 
cycle with 2 phases: a low-dose drug-by-drug addition 
phase followed by an up-dosing phase. Patients were hos-
pitalized during the drug-by-drug addition phase, which 
lasted 18  days, to monitor tolerability and drug-drug 
interactions.
In summary, as schematically depicted in 
Supplementary Material 2, the treatment started with 
temozolomide (20  mg/m2 BSA b.i.d.) and aprepitant 
(80 mg q.d.) on day 1, followed by the addition of 1 drug 
every 2  days (day 3, day 5 etc.) at the low-dose level. 
The last drug (auranofin) was added on day 17. On day 
19, the up-dosing phase started with the dose of only 
one drug being increased every 2  days. The doses of 
temozolomide and aprepitant remained unchanged, 7 
drugs were up-dosed only once and 1 drug (ritonavir) 
was up-dosed twice.
After reaching target doses of all drugs, the regimen 
remained unchanged until side effects mandated dose 
modifications and/or drug pausing or until tumor progres-
sion occurred. While the study was locked after the last 
recruited patient had completed 12 months of treatment, 
patients without tumor progression continued to receive 
the CUSP9v3 regimen beyond that point.
Safety and Dose Modifications
In addition to the potential drug-drug interactions to be 
monitored, we assessed the cumulative toxicity of the 
regimen. Employing the summary of product character-
istics of each of the 10 drugs, we were able to identify 
the side effects most likely to occur during treatment. By 
developing a simple algorithm based on the frequency 
of each side effect (from very common [occurs in ≥ 1/10 
patients] to very rare [occurs in < 1/10 000 patients]), 
we elaborated a strategy for dose modifications, dose 
re-escalations, and on-hold rules. For instance, in case 
of fatigue, no action would be taken for grade 1 or grade 
2 fatigue. If grade 3 fatigue occurred, the first drug on a 
hierarchical list specific for fatigue was to be held until 
grade 2 or lower was reached and resumed at the same 
level. Additional drugs were to be held in the absence of 
resolution of symptoms.
During the induction cycle and the first 2 treatment 
cycles, adjustments (dose reductions and drug pausing) 
were allowed to accommodate the patients’ individual 
tolerability of the regimen. These modifications were dis-
cussed by a team comprising a neurosurgeon (M.-E.H.), an 
oncologist (R.M.-S.), a pharmacologist (O.Z.), and a psychi-
atrist (R.E.K.). For each patient, the regimen tolerated at the 
time of completion of the second treatment cycle (around 
day 90) was used to assess the primary endpoint.
Response Assessment
Response to study treatment was determined by neurolog-
ical examination and contrast-enhanced magnetic reso-
nance imaging (MRI) using the RANO criteria. Assessment 
was done at week 6, week 10 and then every 8 weeks. We 
used the best overall response, i.e., the best response re-
corded from the start of the treatment, as a secondary 
endpoint.
Statistical Analysis
Study data were analyzed by means of descriptive methods 
using frequencies (absolute and relative values) for cate-
gorical data as well as median and range for metric data. 
The Kaplan-Meier method was used to calculate PFS and 
OS. The median PFS and OS, respectively, are presented 
along with their corresponding 95% confidence intervals 
(CI). All analyses were performed using SAS (version 9.4, 
www.sas.com) and R (version 3.5.2, www.r-project.org).
Results
Patients Characteristics
Ten patients were included between August 2016 and 
April 2018. A total of 12 patients were screened. One pa-
tient could not be included because of high serum trans-
aminases and one because of acute deep vein thrombosis. 











Demographic characteristics of the 10 included patients are 
presented in Table 2.
Safety
The defined Pocock-type safety boundaries for stopping the 
trial were not crossed at any time. Nine patients completed 
at least 2 treatment cycles. At the end of the second treat-
ment cycle, no patient had experienced any unmanageable 
grade 3–4 toxicity, and all patients had received at least 7 
of the 10 drugs, given at ≥ 50% of the target doses. The pri-
mary endpoint was therefore met. Most frequently paused 
were ritonavir (for ataxia and fatigue), temozolomide (for 
diarrhea, nausea and laboratory abnormalities), captopril 
(for diarrhea and nausea), and itraconazole (for diarrhea 
and laboratory abnormalities) while ritonavir (for gait dis-
turbance) and captopril (for fatigue) were most frequently 
dose-reduced.
All patients experienced at least one adverse event (AE) 
of any grade (Table 3) and 7 patients (70%) experienced at 
least one grade 3–4 AE, including 2 with at least one grade 
4 AE. Ten AEs occurred in 5 or more patients. These AEs are 
presented in Table 3 with their grades and the drug(s) to 
which the respective AE was most likely related. All grade 
3–4 AEs are presented in Table 4, grouped by classes, and 
listed with the drug(s) to which the AE was attributed or 
deemed possibly related. For all central nervous system 
AEs, no direct relationship could be established between 
the suspected drug and the respective AE because of the 
underlying disease.
All but one of the AEs attributed to CUSP9v3 drugs 
ceased upon pre-specified, targeted dose reduction or drug 
pausing within a range of 0 to 4 weeks (median 2 weeks; 
median number of drug modifications necessary to revert 
an AE: 1.5). None of the AEs that had ceased upon dose re-
duction or drug pausing recurred after the suspected drugs 
were reinstated.
Efficacy
Best overall response was stable disease (SD) in 6 pa-
tients and progressive disease (PD) in 4 patients (Table 5). 
Median duration of response was 8 (range 1–11) months in 
responders at the time of data lock. For 5 patients, SD was 
ongoing at the time of reporting. Three patients developed 
no detectable tumor on MRI during study treatment but 
would not be assigned “complete response” according 
to RANO because their tumor was “non-measurable” on 
MRI (ie, had maximal diameters of < 10 mm × 10 mm) at 
study entry. However, early recurrence had been initially 
diagnosed by external radiologists and was confirmed 
by the trial’s neuroradiologist (Be.S.) on the basis of a > 
25% increase of “non-measurable” disease according 
to RANO.
Progression-free survival and OS are presented in Figure 
1 and Figure 2, respectively. Both PFS and OS at 12 months 
were 50% with large confidence intervals because of 
the small sample (95% CI, 27–93%). Table 3 shows each 
patient’s individual PFS together with their disease charac-
teristics and treatment prior to study entry.
Discussion
In this phase Ib/IIa trial in recurrent or progressive GBM, 
we found that 9 carefully selected non-oncological re-
purposed drugs together with twice daily 20 mg/m2 BSA 
  
Table 2.  Demographic Characteristics of the 10 Patients Included in 
the CUSP9v3 Trial
Characteristics N (%)
 Sex  
 Male  6 (60)
 Female  4 (40)
 Median age at diagnosis in years (range) 41 (25–60)
Type of GBM  
 Primary  8 (80)
 Secondary  2 (20)
KPS at baseline  
 100  4 (40)
   90  2 (20)
   80  1 (10)
   70  3 (30)
Recurrence/progression at inclusion  
 First  6 (60)
 Second  4 (40)
Median time between first diagnosis and start of 
CUSP9v3 in months 
16
Tumor location at time of study entry  
 Frontal lobe  2 (20)
 Temporal lobe  2 (20)
 Parietal lobe  1 (10)
 Disseminated—basal ganglia  1 (10)
 Disseminated—midbrain and brainstem  2 (20)
 Disseminated—callosal  2 (20)
Initial extent of resection  
 Gross total  7 (70)
 Subtotal  3 (30)
MGMT promoter status  
 Hypermethylated  6 (60)
 Non-hypermethylated  4 (40)
IDH1/2 status  
 Mutated  2 (20)
 Wild-type  8 (80)
Prior therapies  
 Surgery 10 (100)
 Radiotherapy 10 (100)
 Temozolomide 10 (100)
 Bevacizumab  1 (10)
 Tetrahydrocannabinol  1 (10)
 TTFieldsTM  1 (10)
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temozolomide was safe and generally well-tolerated if 
individual dose adjustments were performed. CUSP9v3 
is well-enough tolerable to be started in outpatients and 
to be fully introduced over a shorter time period than the 
35 days that we used. The most frequent AEs are not ex-
pected to cause management problems as they are well-
known to physicians treating patients with recurrent GBM.
Other trials in pediatric and adult high-grade glioma 
had reported the safety of various multi-agent regimens 
combining chemotherapy with repurposed drugs, using a 
range of 4–7 agents.31–33 Here we show that it is possible 
to combine 9 repurposed drugs given a careful evalua-
tion of potential drug-drug interactions and cumulative 
toxicity. Knowing that many non-oncological drugs target 
pathways relevant to GBM, precision oncology approaches 
could expand their armamentarium by evaluating non-
cancer drugs and combining them with classical cancer 
drugs.34,35 Such was recently reported in a trial in diffuse 
intrinsic pontine glioma.36 As strategies targeting cell 
membrane marker-defined glioblastoma cells may be lim-
ited,37 CUSP9v3 is consciously intended as a biomarker-
independent approach.
During the protocol development for this trial, a hier-
archical drug list had been developed (based on AE in-
formation contained in each drug’s summary of product 
characteristics) that correlated AEs to ranked sequences of 
drugs to be halved in dose or paused until pre-specified 
lower Common Toxicity Criteria of Adverse Events 
grades were reached. If that was not the case within 
3 days, the next drug on the hierarchical list was halved 
in dose or paused etc. This strategy proved successful in 
managing AEs.
Noteworthy, the 3 AEs most frequently observed in this 
trial were nausea, headache and fatigue. While a causal re-
lationship between the CUSP9v3 drugs and these cardinal 
AEs cannot be excluded, these symptoms may also be 
caused by the underlying disease itself and/or its primary 
treatment, temozolomide.
While the trial was not designed to assess the efficacy 
of the CUSP9v3 regimen, we observed that 5 patients pro-
gressed quickly, dying within a range of 1.5–7 months. The 
5 other patients did well on treatment, all 5 having a PFS 
of 12 or more months (range 12–29 months at the time of 
data lock). In recurrent GBM, single-agent trials have re-
ported PFS at 6 months of up to 20–30%.38,39 The rate of 
patients being alive and progression-free at 6 months has 
been suggested as an appropriate surrogate endpoint for 
predicting OS.40
However, the small number of patients prevents any in-
terpretation about the efficacy of the CUSP9v3 regimen. 
Another limitation is that the trial did not require histopath-
ological confirmation of recurrence prior to study entry. 
Therefore, despite radiological judgement and reasonable 
time periods between the completion of radio- and chemo-
therapy on the one hand and the beginning of the study on 
the other hand (12 and 4 weeks, respectively), patients with 
a favorable course could have had pseudo-progression 
upon starting CUSP9v3. This issue of pseudo-progression 
is inherent to non-randomized trials in the recurrent 
setting.
One hypothesis that is supported by the pronounced di-
chotomy of response to CUSP9v3 is that CUSP9v3 may be 
more effective in patients with slower proliferating tumors 
and/or lower tumor burden, suggesting that this regimen 
may have a role in a prophylactic maintenance setting after 
first-line treatment.
Drug repurposing represents a large source of therapeutic 
options in cancer.41,42 In GBM in particular, notably 76 repur-
posed drugs recently were reported as potentially useful.34 
The selection of the 9 drugs to be included in CUSP9v3 
was a long iterative process within a conceptual frame-
work that considered the specific and relevant preclinical, 
  
Table 3.  Number of Patients Experiencing at Least One Adverse Event (AE) by Grade and Related Drugs, for the Most Frequent AEs
All grades Grade 3–4 Grade 1 Grade 2 Grade 3 Grade 4 Drug to which AE was most frequently 
attributed (or possibly related)
All AEs 10 7 10 9 7 2  
Most frequent 
AEs
       
 Fatigue 9 1 2 6 1 - Temozolomide
 Nausea 9 1 4 4 1 - Temozolomide (all 10 drugs deemed 
possibly related for at least 1 patient)
 Headache 8 1 5 2 1 - Sertraline
 Seizure 6 2 2 2 2 - Sertraline
  Lymphocyte 
count decrease
6 6 - - 5 1 Temozolomide
 Diarrhea 5 - 4 1 - - Temozolomide (followed by minocycline 
and sertraline)
 Dysgeusia 5 - 5 - - - Sertraline
  Gait distur-
bance
5 3 - 2 3 - Sertraline
 Bradycardia 5 - 5 - - - Captopril
 Tremor 5 - 4 1 - - Sertraline
  











pharmacological, and empirical features of each drug in ad-
dition to the 5 criteria listed in the Introduction. It should not 
be assumed that combining other repurposed non-cancer 
drugs will automatically yield similar results; other regi-
mens may prove more or less toxic or more or less effective.
In the common aggressive cancers, and especially in 
GBM, phenotypic spatial and temporal heterogeneity, 
in both stem and non-stem cell  subsets, is a dynamic 
process responding to treatment interventions and 
driven further by hypoxia.43–45 In addition, GBM may be 
considered a collection of mutually interacting, mutually 
supporting cellular subpopulations46 demanding the use 
of a multi-drug combination to achieve prolonged treat-
ment response.
Conclusions
We report here the first clinical trial of the CUSP9v3 regimen 
in recurrent or progressive GBM. The treatment regimen 
was safe under clinical, laboratory and electrocardiogram 
monitoring. A multicenter randomized controlled phase II/III 
trial is in preparation to assess the efficacy of the CUSP9v3 
regimen in GBM.
  
Table 4.  List of all Grade 3–4 Adverse Events (AEs) and Related Drugs
AE N Drug(s) to which AE was 
attributed
Drug(s) to which AE was possibly 
related
Liver and pancreatic enzymes    
 ALAT increased 4 Temozolomide Minocycline, celecoxib, captopril, 
itraconazole, ritonavir, auranofin
 ASAT increased 1 Temozolomide Aprepitant, minocycline, celecoxib, 
captopril, ritonavir
 GGT increased 1 Temozolomide Minocycline, celecoxib, captopril, 
ritonavir
  Lipase increased 1  - Temozolomide, itraconazole
Hematology    
  Lymphocyte count de-
creased
8 Temozolomide, itraconazole, 
ritonavir, auranofin
Minocycline, celecoxib, captopril, 
itraconazole, ritonavir, auranofin
 White blood cell decreased 1  - Temozolomide, minocycline, celecoxib, 
itraconazole, ritonavir, auranofin
 Platelet count decreased 3 Temozolomide  
Central nervous system    
 Aphasia 1  -  -
 Ataxia 2  - Sertraline, celecoxib
 Confusion 1  - Sertraline, captopril
 Edema, cerebral 2  -  -
 Gait disturbance 5  - Sertraline
 Headache 1  -  -
 Hypoglossal nerve disorder 1  -  -
 Psychosis 1  -  -
 Pyramidal tract syndrome 2  -  -
 Seizure 2  - Sertraline
 Vagus nerve disorder 1  -  -
Gastro-intestinal    
 Dysphagia 1  -  -
 Nausea 1  - All 10 drugs
Other    
 Fatigue 1  - Temozolomide
 Hypotension 1  - Captopril
 Lung infection 1  - Temozolomide
  Muscle weakness lower 
limb
1  -  -
 Thromboembolic event 1  -  -
ALAT, Alanine aminotransferase; ASAT, Aspartate aminotransferase: GGT, Gamma-glutamyltransferase.
  



























Figure 1. Progression-free survival since CUSP9v3 start.
  
  







Prior treatment besides 









1 31 100 Re-resection Methylated/mutated SD 29 Alive
2 48 80 Re-resection, re-RT Methylated/wild-type PD 2 Deceased
3 60 70 Bevacizumab Non-methylated/wild-
type
PD 0 Deceased
4 53 100 - Methylated/wild-type SD 21 Alive
5 41 100 Re-resection, 
tetrahydrocan nabinol
Methylated/wild-type SD 21 Alive
6 41 70 - Methylated/wild-type PD 0 Deceased
7 30 90 - Non-methylated /
wild-type
SD 17 Alive
8 47 70 Re-resection Methylated/wild-type PD 2 Deceased
9 25 90 Re-resection Non-methylated /
mutated
SD 3 Deceased
10 27 100 TTFieldsTM Non-methylated /
wild-type
SD 12 Alive
* All 10 patients had been treated with surgery, chemo-radiotherapy and adjuvant temozolomide.
ID, identification; IDH1/2, isocitratdehydrogenase 1 or 2 gene; KPS, Karnofsky Performance Score; MGMT, O6-methylguanine-DNA 
methyltransferase; PD, progressive disease; PFS, progression-free survival; RT, radiotherapy; SD, stable disease.
  











This pilot study met its primary endpoint with no un-
predicted side effects resulting from the combination of 
drugs, and there was a signal of a potential positive effect 
of CUSP9v3 that should be tested in future trials.
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